Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2720]

Editor's Choice for June 2018

Prof Gordon McVie - Founding Editor, ecancer

Editor's Choice for June 2018 ( Prof Gordon McVie - Founding Editor, ecancer )

Disease management for mCRPC

Prof Nicholas Mottet, Dr Philipp Mandel and Prof Amit Bahl

Disease management for mCRPC ( Prof Nicholas Mottet, Dr Philipp Mandel and Prof Amit Bahl )

Advanced Prostate Cancer - The evolving landscape and targeted therapies

Prof Nicholas Mottet, Prof Amit Bahl, Prof Piet Ost and Dr Inge Van Oort

Advanced Prostate Cancer - The evolving landscape and targeted therapies ( Prof Nicholas Mottet, Prof Amit Bahl, Prof Piet Ost and Dr Inge Van Oort )

Highlights from PROSCA 2018: Imaging, biomarkers and genetic testing

Prof Noel Clarke, Prof Hardev Pandha, Prof Amit Bahl and Dr Nina Tunariu

Highlights from PROSCA 2018: Imaging, biomarkers and genetic testing ( Prof Noel Clarke, Prof Hardev Pandha, Prof Amit Bahl and Dr Nina Tunariu )

Expert insight: The basic medical understanding of neutropenia and general...

Dr Matti Aapro - Genolier Cancer Center, Genolier, Switzerland

Expert insight: The basic medical understanding of neutropenia and general clinical considerations ( Dr Matti Aapro - Genolier Cancer Center, Genolier, Switzerland )

MASCC 2018: Chemotherapy-induced neutropenia and the role of G-CSFs

Prof Jean Klastersky and Prof Bernardo Rapoport

MASCC 2018: Chemotherapy-induced neutropenia and the role of G-CSFs ( Prof Jean Klastersky and Prof Bernardo Rapoport )

CDK6 a transcriptional regulator in AML

Prof Veronika Sexl - University of Veterinary Medicine of Vienna, Vienna...

CDK6 a transcriptional regulator in AML ( Prof Veronika Sexl - University of Veterinary Medicine of Vienna, Vienna, Austria )

ASCO 2018 conference round up

Dr Bishal Gyawali and Will Davies

ASCO 2018 conference round up ( Dr Bishal Gyawali and Will Davies )

Treating CLL with obinutuzumab

Dr Valentin Goede - St. Marien-Hospital, Cologne, Germany

Treating CLL with obinutuzumab ( Dr Valentin Goede - St. Marien-Hospital, Cologne, Germany )

Half of CLL patients who relapse on ibrutinib harbour BTK/PLCG mutations

Dr Lydia Scarfo - San Raffaele Scientific Institute, Milan, Italy

Half of CLL patients who relapse on ibrutinib harbour BTK/PLCG mutations ( Dr Lydia Scarfo - San Raffaele Scientific Institute, Milan, Italy )

Venetoclax in patients with previously treated WM

Prof Jorge Castillo - Dana-Farber Cancer Institute, Boston, USA

Venetoclax in patients with previously treated WM ( Prof Jorge Castillo - Dana-Farber Cancer Institute, Boston, USA )

ICLL07 FILO study: Minimal residual disease still detectable after first line...

Prof Pierre Feugier - University of Lorraine, Nancy, France

ICLL07 FILO study: Minimal residual disease still detectable after first line combination therapy ( Prof Pierre Feugier - University of Lorraine, Nancy, France )

More from ecancer